in Sweden have been reported to the Swedish Cancer Registry. An almost 100% coverage has been achieved by compulsory reporting by clinicians who diagnose a neoplasm, while pathologists and cytologists must report separately any diagnosis of malignancy made on specimens they receive. The site of tumour is coded to a 4-digit diagnostic code based on the 7th revision of the International Classification of Diseases (ICD-7) by the Swedish Cancer Registry (see footnote to Table 1 ). We did not separate acute and chronic leukaemia because acute lymphoid is less than 30% of all lymphoid leukaemia, and because chronic myeloid is less that 20% of all myeloid leukaemia; furthermore, diagnostic criteria for leukaemia have been modified over the years. Basal cell carcinoma of the skin is not registered in the Cancer Registry. The stage of the disease at diagnosis or treatment is not recorded.
Patients
All patients with an initial HLPD diagnosed between 1 January 1958 and 31 December 1996 were retrieved from the Database. Cases of second primary malignancies were extracted if the diagnosis date of the first and second malignancy differed by at least 1 month. Between 1958 and 1996, a total of 3498 patients developed a second primary malignancy among 53 159 HLPD patients.
Statistical analysis
Person-years at risk for second malignancy were accumulated for each subject from the date of diagnosis of the first primary malignancy to that of a second primary malignancy, date of death, date of emigration, or December 31, 1996, whichever came first. Personyears were classified by sex, 5-year age group, 5-year calendar period (1958-1962, 1988-1992, 1993-1996) , 2 types of residential area (3 counties of large cities vs other), 4 occupational groups (farmer, worker, professional and other), time since entry to the cohort (< 1, 1-9 and > 9 years) and family history of HLPD in parents and siblings. A cut-off point of 9 years after the first diagnosis was selected to explore the potential radiotherapy-and chemotherapy-induced risk for second primary malignancies (Travis et al, 1991 (Travis et al, , 1993 Swerdlow et al, 1997 Swerdlow et al, , 2000 Metayer et al, 2000) .
Expected numbers were obtained by assuming that these persons experienced the same cancer incidence as prevailed in the corresponding general population in the Database and site-, sex-, age-, period-, residence-and occupation-specific rates were applied to the appropriate person-years at risk. Standardized incidence ratios (SIR) of a second cancer were taken to be the ratio of observed (O) to expected (E) numbers of second cancers. Confidence intervals (95%CI) for SIR were calculated assuming that the cases followed a Poisson distribution (Esteve et al, 1994) . Because other leukaemia is a mixed group, it will not be considered in further analyses. A total of 1.6% of HLPD (834/53 159) were familial. Familial lymphoma and leukaemia showed an at least 12 years earlier median age of onset than sporadic cases. Among 834 second primary malignancies, 51 (6.1%) had an HLPD-affected parent or sib, including 8 for second HLPD, 4 for melanoma or squamous cell carcinoma of the skin and 39 for solid tumours. Because of the small numbers, familial cases were not analysed separately. Table 2 reports the overall risk of second primary cancer at specific sites after NHL and HD. For NHL patients, there were significant excesses of cancers of the tongue, small intestine, nose (2 of 6 cases were undifferentiated cancers), kidney, skin (squamous Number of patients  18 960  5353  8656  8098  7127  4965  53 159  Male  11 137  3258  5036  5118  3909  2769  31 227  Female  7823  2095  3620  2980  3218  2196  21 932  Familial   b   300  131  93  123  110  77  834  Sporadic  18 660  5222  8563  7975  7017  4888  52 325   Person-years at risk  94 088  46 206  32 255  43 330  21 776  26 535  264 190 Median age at 1st diagnosis (years)  64  41  68  63  59  62  63  Familial  52  29  65  51  40  48  50  Sporadic  64  42  68  63  59  62  63 Median length of follow-up (years) 2.5 5.5 2.5 3.5 1.5 2.5 2. cell carcinoma, SCC), nervous system, NHL, HD and leukaemia, whereas there were significant decreased risks of cancers of the breast, endometrium and prostate. The SIR of 3.54 for SCC of skin was the highest among all solid cancers. For HD patients, significant excesses were seen for cancers of the salivary glands (5 cases, 2 of these undifferentiated), nasopharynx (3 cases, 2 undifferentiated), stomach (18 cases, all but one adenocarcinomas), colon, lung, breast, skin (both melanoma and SCC), nervous system, thyroid, soft tissues and leukaemias. Compared with the general population, NHL and HD patients had an excess of HLPD and skin tumours, but only HD patients were at increased risk for all second solid tumours (SIR = 1.40, 95% CI = 1.24-1.57). Table 3 presents the risks of second malignancies following NHL by sex, age at first diagnosis and follow-up time at selected sites where there was a significant excess. Males and females had a similar risk pattern (increased or decreased) at all selected sites. Increased risks of second malignancy were observed over all age groups and follow-up times for small intestine, nose, skin SCC, NHL, HD and leukaemias. The SIRs for cancers of the tongue, small intestine and skin and for NHL, HD and LL were highest when the age at first diagnosis was under 40 years. An increased risk of breast cancer after NHL was confined to those whose age at first diagnosis was under 40 years, whereas those whose age at first diagnosis was ≥ 40 years had a significantly decreased risk 
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a (data not shown). A significant increase in cancer of the kidney was confined to the first year of follow-up and this may be due to increased surveillance or chance. An excess of bladder cancer was confined to the period > 9 years of follow-up (data not shown). Table 4 reports the risks of second malignancies following HD by sex, age at first diagnosis and follow-up time at selected sites where there was a significant excess. Males and females showed a similar risk pattern (increased or decreased) for cancers of salivary glands, lung, skin SCC, nervous system, thyroid and soft tissue and for haematolymphoproliferative tissues except multiple myeloma; by contrast, an increased risk of cancer of the nasopharynx, stomach, colon and melanoma skin was confined to male HD patients. An excess of female breast cancer was confined to patients whose initial diagnosis age was under 40 years and the period > 9 years of follow-up. Increased risks of cancers of colon, skin and nervous system, NHL and leukaemia were observed over all age groups and follow-up periods over 1 year. Increased risks of cancers of salivary glands, nasopharynx, stomach, lung, thyroid and soft tissues were mainly found in patients whose age at first diagnosis was under 55 years and ≤ 1 year since HD diagnosis. An increased risk of melanoma was seen in those under 65 years at first diagnosis and follow up period ≤ 9 years, with the trend decreasing from initial diagnosis. Table 5 reports risks following myeloma and leukaemia by subgroup and follow-up time for second malignancies of skin, nervous system, haematolymphoproliferative tissues and all solid tissues. After myeloma, a significant increase was seen for SCC of the skin in males but not in both sexes; for NHL the overall SIR was increased. After lymphoid leukaemia, a significant increase in SIR was seen for SCC of the skin and NHL during period ≥1 year of follow-up and overall, for cancer of the nervous system during period <1 and > 9 years of follow-up and overall, for HD, lymphoid and myeloid leukaemia during 1-9 years of follow-up and overall. After myeloid leukaemia, a significantly increased risk was found only for recurrence. No excess of melanoma was observed (data not shown). The SIR for melanoma was highest after lymphoid leukaemia, 1.53 (n = 17, 95% CI, 0.89-2.43); 15 of the cases were men, SIR 2.02 (95%CI, 1.13-3.34).
DISCUSSION
The Swedish Family-Cancer Database was used in the present study and 6.1% of second HLPD cases had a family history of HLPD, which was higher than that for first HLPD (1.6%). The patients with a family history presented with their first HLPD on average 12 years earlier than patients with a sporadic disease. Our results are based on one of the largest cohorts of patients with HLPD studied to date (totalling 53 159 patients, 264 190 person-years), enabling us to analyse site-specific risk of second cancer following HLPD. The large dataset permits description of age and latency patterns for second cancer risk at a broad spectrum of anatomic sites. In addition, the estimation of SIRs was based on adjustment for period, residence and socio-economic status, which may be potential confounding factors and mainly unadjusted in previous studies. Period is important, particularly for NHL, which has increased in incidence throughout the follow-up period, and even for other HLPDs because of changes in treatment. Although our data lack information about treatment, we divided the follow-up time into 3 periods, <1, 1-9 and > 9 years. The period > 9 years of follow-up may reveal the effects due to radiotherapy and chemotherapy at most solid tumours but leukaemias appear earlier (Travis et al, 1991 (Travis et al, , 1993 Swerdlow et al, 1997 Swerdlow et al, , 2000 Metayer et al, 2000) ; the first year of diagnosis may include recurrences and reveal the effects of medical surveillance. We consider the effect of follow-up in subsequent discussion. HLPDs are a number of heterogeneous but related conditions. However, misclassification, particularly NHL to HD, may have taken place in the past (Travis et al, 1991; Abrahamsen et al, 1997; Kumar et al, 1997) . The distinction between the related conditions, NHL and chronic LL, may also have been unclear in the past (Adami et al, 1995) . The classification of HLPDs has undergone many changes during the past decades and whether these changes have affected the broad categories used in the present study remains unknown.
Treatment of HLPDs has undergone major changes during the period of the present study, 1958-96. Chemotherapy and radiotherapy have been used throughout the period but new antineoplastic agents and more aggressive therapies have been introduced (Adami et al, 1995) . For some HLPDs, prognosis has improved markedly and, for example, the 5-year survival from HD has improved 3-fold in Sweden between 1962 and 1988 (Stenbeck and Rosen, 1995) . The respective improvements for NHL, multiple myeloma and leukaemias have been about 1.5-fold. Radiotherapy and many types of chemotherapy carry a risk for second cancers and treatment of HD is known to increase the risks of acute leukaemia, NHL and of lung, gastro-intestinal, breast, thyroid, bone and connective tissue cancer (Kumar et al, 1997; Metayer et al, 2000; Swerdlow et al, 2000) .
NHL, HD, leukaemia and myeloma
Many studies have been published on second cancers after NHL. Common findings have been increases in acute leukaemia, cancers at lung, bladder, soft tissues, thyroid and kidney, melanoma and HD (Travis et al, 1991 (Travis et al, , 1993 Brennan et al, 2000) . Excesses in melanoma and, particularly, skin SCC have been observed after NHL and chronic lymphoid leukemia (Adami et al, 1995; Levi et al, 1996) . The present study, only second to the Adami study in accumulated person-years, noted increases in tongue, small intestinal, nasal, bladder, skin (SCC but not melanoma), and nervous system cancers, in addition to all types of HLPD. Many of these increases in earlier studies, have been ascribed to the effects of treatment, though other possible causes have probably been overlooked (Travis et al, 1991) . In contrast, we found no increases in gastro-intestinal (except for small intestine) and lung cancers nor, notably, in melanoma. On the other hand, details of nasal cancer (our SIR 3.25) have been reported in only one study and no increase was noted (Brennan et al, 2000) . We have recently drawn attention to the occurrence of nasal cancer as a second cancer after skin SCC and speculated on the possible aetiological role of EBV, perhaps in immunocompromised individuals Dong, 2000b, 2000c) . We have recently noted an excess of second NHL after nasal cancer (Dong and Hemminki, 2001b) . These epidemiological findings may not be fortuitous. Another site, which was increased after NHL, was the nervous system; this site was also in excess after lymphoid leukaemia and the association is thus unlikely to be fortuitous. An increase has also been noted in a previous study (SIR 2.33 ) and in another one for males only (Travis et al, 1991 (Travis et al, , 1993 . Treatment effects in nasal and nervous system tumours were not suggested when the risks were analysed according to the follow-up time (Table 3) .
NHL and HD were increased after each other, with high SIRs of 5.5-6.5 (Table 2 ). Both have been treated with aggressive therapy. Yet the spectrum of second malignancies observed was quite different: among solid tumours only skin SCC and nervous system cancers were increased after both NHL and HD. One reason for the different effects may be in the age distribution; the median age of the first HD diagnosis was 41 years compared to 64 for NHL. There may also be other biological explanations. Many large follow-up studies have been carried out after HD with the aim of quantifying carcinogenic risks of radiation and chemotherapy (Swerdlow et al, 1997 (Swerdlow et al, , 2000 Metayer et al, 2000) . All the sites that were increased in the present study were also noted in these previous studies, including salivary glands and upper aerodigestive tract (without further subdivision), but with the notable exception of skin cancer. The SIR for nonmelanoma skin cancer was 1.4 in the English study and it was excluded from further analysis because registration was assumed to be seriously incomplete (Swerdlow et al, 2000) . Skin cancer and melanoma are discussed below.
It is of interest that nasopharynx (SIR 9.15) and stomach (SIR 1.69) together with HD and certain types of NHL are considered as potentially EBV-related (IARC, 1997) . The increases at salivary glands and nasopharynx were the highest among second malignancies after HD. Histology showed that more than expected of these tumours were undifferentiated cancers though the number of cases was small. Analysis by follow-up time (Table 4) showed increases in SIR towards the end of follow-up, suggesting either treatment related effects or possibly slow malignant viral transformation.
Myeloma was followed by an excess of NHL and leukaemia. Lymphoid leukaemia was followed by excesses of skin SCC (SIR 5.28), nervous system cancer (1.93), and many types of HLPD. The distribution of skin and nervous system cancers after diagnosis of lymphoid leukaemia gave no suggestion of being treatment-related.
Melanoma and SCC of skin following HLPD
UVR is a common risk factor for melanoma and skin SCC. For skin SCC, the total life-time UVR-dose is considered important; for melanoma high intermittent exposures in childhood and adolescence are considered important (Adami et al, 1995; English et al, 1997) . A second aetiological factor is defective immune function and skin SCC and NHL are greatly increased in organ transplant patients (Kinlen, 1992; IARC, 1997) . The third aetiological factor could be chemo-and radiotherapy, radiation being known to increase the risk of skin SCC though data on chemotherapy are not consistent (IARC, 1990; Metayer et al, 2000; Swerdlow et al, 2000) .
An excess of melanoma after NHL and chronic lymphoid leukaemia has been observed in most previous studies (Travis et al, 1991 (Travis et al, , 1993 Adami et al, 1995; Levi et al, 1996; Brennan et al, 2000) , whereas our data were negative for NHL and only marginally positive for lymphoid leukaemia. After HD, melanoma was increased but the highest SIR was found immediately after the initial diagnosis, suggesting surveillance bias. In most of the previous studies, cited above, the risks for melanoma were also high immediately after the initial diagnosis. Taken together, the data suggest a modest increase of melanoma risk after NHL and chronic lymphoid leukaemia.
The case for skin SCC is much stronger. In an earlier study the risks after both NHL and chronic lymphoid leukaemia were more than 2 times higher for skin SCC than melanoma (Adami et al, 1995) . Excesses of NHL and chronic lymphoid leukaemia have been noted after skin SCC (Adami et al, 1995; Levi et al, 1996) . An increase in all lymphomas, 80% of which were NHL, has been observed even after in situ SCC of skin, a benign tumour for which the primary treatment has been surgery only (Hemminki and Dong, 2000c) . The present data were convincing showing high SIRs for skin SCC after NHL, HD and lymphoid leukaemia. The excess of skin SCC after HD, only previously documented for non-melanoma skin cancer (Swerdlow et al, 1997) was robust (n = 23, SIR 2.89, 95%CI, 1.83-4.35). There was no evidence that the excess of skin SCC as a second malignancy was due to surveillance bias or therapy.
Conclusions
There has been much interest in the aetiology of NHL, melanoma and skin SCC because they have increased in most Western countries, in Sweden more than any other cancer (Centre for Epidemiology, 1999) . Our data unify the fragmentary earlier evidence to point to the aetiological links between NHL, HD, chronic lymphoid leukaemia and skin SCC. The common mechanism may be a (possibly) transient impairment of immunological surveillance that allows escape of tumours cells and formation of SCC. Depressed immune function may also be a contributing cause for the initial NHL, HD and lymphoid leukaemia, and the long-term chemo-and radiotherapy may increase such depression. This interpretation will not explain the worldwide temporal increase in NHL alone among HLPDs (Cartwright et al, 1994) . However, data on the temporal trends on subtypes of leukaemias are limited and those on HD show complex patterns of increase among young and large decrease among old patients (Abrahamsen et al, 1997; Chen et al, 1997) . UVR-induced immunosuppression has been suggested to contribute to the increasing trends in both NHL and melanoma, or, as consistent with our results, in NHL and skin BCC (Cartwright et al, 1994; Adami et al, 1995; Levi et al, 1996; Brennan et al, 2000) . There is evidence from epidemiological studies on melanoma that use of sunscreens is a risk factor for melanoma (IARC, 2001) . Among the 15 case-control studies on melanoma reviewed by the IARC working group, 8 showed significantly higher risks among sunscreen users. Although some of these studies may have problems with confounding, the increasing use of sunscreens deserves further research. Allergies, asthma and atopy are other immune-related groups of diseases that have been increasing in prevalence in the developed world. In these conditions the immune system is hyperactive, and there is evidence for allergies protecting against NHL (Volkers, 1999) .
We observed associations to putative EBV-related sites, salivary glands, nasopharynx and stomach after HD; nasal cancer was increased after NHL but the link to EBV remains to be established. Undifferentiated cancers were in excess at sites other than the stomach and the number of cases was too small to allow conclusions. Nervous system cancer was the only solid tumour, together with skin SCC, that was increased after NHL, HD and lymphoid leukaemia.
